However, with Eli Lilly's valuation at around $900 billion today, expectations are also sky-high. That can make it difficult ...

Eli Lilly's stock is a bit expensive, even with a bit of a decline this year.

Eli Lilly (LLY) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over the ...

Eli Lilly has been a growth beast in recent years, but its valuation has gotten fairly high along the way.

With short-term returns turning negative, analysts are reassessing Lilly's high valuation, reminding the market that even ...

LLY's shares fall 5% in a month amid pricing fears and obesity-drug rivalry, but booming Mounjaro and Zepbound sales and a deep pipeline keep growth hopes alive.

Eli Lilly beat earnings soundly yesterday. Today, the stock is selling off on new competition from Hims & Hers Health. One day after reporting Q4 earnings, Eli Lilly (NYSE: LLY) shares tumbled 6% ...

Eli Lilly (NYSE: LLY) stock has pulled back 2.9% year-to-date to around $1,044, and institutional investors have been accumulating shares during the pullback, according to recent filings. The Earnings ...

Eli Lilly's market share in obesity drugs exceeds 60%, but further gains may be capped as competition escalates. Read why LLY ...

Is LLY a good stock to buy? We came across a bullish thesis on Eli Lilly and Company on Investomine’s Substack. In this article, we will summarize the bulls’ thesis on LLY. Eli Lilly and Company’s ...